Therefore, we propose that the combined therapeutic efficacy may be partially mediated by cooperative inhibition of PepT1, a transporter that is overexpressed in the colonic epithelium of IBD patients and believed to facilitate uptake of bacterial pro-inflammatory peptides [29,32,45]. This evidence concerns the gene SLC15A1 and inflammatory bowel disease.